BioInvent: More Encouring Data from Lymphoma Program - Redeye
Redeye comments on Bioinvent’s latest update on the phase I/IIa clinical trial with BI-1206 in indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
ANNONS
Redeye comments on Bioinvent’s latest update on the phase I/IIa clinical trial with BI-1206 in indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).